Strong Q1 sales of $137.3M showcase Madrigal Pharmaceuticals, Inc.'s Rezdiffra's growth in non-cirrhotic NASH. Click for my ...

Madrigal Pharmaceuticals secures global rights to SYH2086, aiming to enhance MASH treatment with innovative combination ...

U.S. drugmaker Madrigal Pharmaceuticals has struck a licensing deal with CSPC Pharmaceutical Group that could be worth more than $2 billion for the Chinese company if it results in a new drug for a ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for ...

CEO touts 'amazing' sales success of new drug, but firm's stock slumps Montco firm's shares soar on huge sales increase of ...

Conshohocken, Pa. Friday, August 1, 2025, 15:00 Hrs [IST] ...

Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

Madrigal Pharmaceuticals said on Wednesday it has entered into an up to $2 billion global license agreement with CSPC Pharmaceutical to develop an oral GLP-1 drug for a type of liver disease. The U.S.

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...